Structured Evaluation (AIMS-EVAL-2025-01)
24 / 24
100% Hand-Verified Resistance Computations
Critical Carbapenem Signals (R1)
6 / 6
100% Capture of Predefined CRE/CRPA Signals
Low-Denominator False Alarms (R5)
6 Suppressed
Prevented Unstable Small-Sample Distortion
Prospective Observational Validation
14 Signals
Early-Warning Clusters Missed by Routine Review
Interactive Organism × Antimicrobial Resistance Surveillance Matrix
Demonstrating AIMS Layer 2 longitudinal resistance computations with automatic low-denominator statistical gating (Modification M-1 / Rule R5).
Organism (Normalized Taxonomy) Antimicrobial Agent CLSI Breakpoint Class Evaluated Isolates (n) Resistant (%R) Intermediate (%I) Susceptible (%S) AIMS Statistical Gate & Surveillance Status
AIMS Rules-Based Alerting Engine (R1–R5) & Mandatory Human-in-the-Loop Disposition Queue
Every computational signal requires documented review by a certified Medical Technologist M(ASCP) or Antimicrobial Stewardship Pharmacist prior to clinical/epidemiological action.
9 / 9 Alerts Reviewed & Dispositioned
Alert ID Rule Triggered Organism & Agent Unit / Location MIC / Phenotype Signal Severity Human-in-the-Loop Disposition Interactive Action
Suppressed Low-Denominator Signals (Rule R5 Statistical Safeguard)
Demonstrating how AIMS prevents alert fatigue and misleading percentage spikes when isolate counts fall below minimum denominator thresholds.
Suppression ID Organism & Agent Raw Unadjusted Rate Sample Size (n) AIMS Rule R5 Action Clinical Governance Rationale
SUP-2025-01 Klebsiella pneumoniae — Amikacin 50.0% R n = 2 Auto-Suppressed (n < Threshold) Prevents false outbreak escalation from 1/2 resistant isolates; routed to cumulative watch list.
SUP-2025-02 Pseudomonas aeruginosa — Ceftazidime 100.0% R n = 1 Auto-Suppressed (n < Threshold) Single-isolate artifact suppressed from population trend rate; individual AST still reported.
SUP-2025-03 Acinetobacter baumannii — Gentamicin 66.7% R n = 3 Auto-Suppressed (n < Threshold) Below minimum statistical stability threshold (CLSI M39 alignment).
SUP-2025-04 Escherichia coli — Nitrofurantoin (Inpatient) 33.3% R n = 3 Auto-Suppressed (n < Threshold) Sub-threshold denominator flagged; suppressed from automated stewardship alert queue.
SUP-2025-05 Enterobacter cloacae — Cefepime 50.0% R n = 2 Auto-Suppressed (n < Threshold) Small-denominator instability prevented per AIMS Modification M-1.
SUP-2025-06 Staphylococcus aureus — Linezolid 0.0% R (1 Indeterminate) n = 2 Auto-Suppressed (n < Threshold) Insufficient denominator for trend inference; routed to manual bench verification only.
Four-Layer Functional Architecture (Implemented Across Six Technical Stages)
Designed by Adaora N. Ofole to bridge routine bench-level clinical microbiology with actionable epidemiological intelligence.

Layer 1: Data Standardization & QC

Ingests routine LIS/AST outputs and normalizes organism taxonomy, S/I/R interpretations, numeric MIC values, specimen sources, patient locations, and ISO timestamps while enforcing first-isolate deduplication.

Layer 2: Surveillance & Antibiogram Layer

Computes longitudinal resistance rates by organism, antimicrobial agent, ward/facility, and time window, transforming fragmented patient-level reports into structured surveillance views.

Layer 3: Analytical & Alerting Engine (R1–R5)

Executes rules-based multidimensional pattern recognition (R1–R5) to detect critical carbapenem resistance, temporal spikes, and spatial clusters—with supervised ML training deferred by design until governed clinical datasets are accrued (Modification M-8).

Layer 4: Mandatory Human-in-the-Loop Governance

Enforces professional disposition vocabulary, override audit logging, and multilayer review aligned with FDA GMLP, CLSI M100, CDC ARLN, and CMS CLIA standards.

Core Relational SQL Schema & Surveillance Transformation Specification (Excerpt — Exhibit 29)

-- AIMS Framework Core Relational Schema & R1-R5 Surveillance View (Adaora N. Ofole)
CREATE TABLE aims_isolates_normalized (
    isolate_id VARCHAR(64) PRIMARY KEY,
    patient_deid_hash VARCHAR(64) NOT NULL,
    facility_code VARCHAR(32) NOT NULL,
    ward_unit VARCHAR(64) NOT NULL,
    specimen_source VARCHAR(64) NOT NULL,
    collection_timestamp TIMESTAMP NOT NULL,
    organism_ncbi_taxid VARCHAR(32) NOT NULL,
    organism_canonical_name VARCHAR(128) NOT NULL,
    first_isolate_window_flag BOOLEAN DEFAULT TRUE
);

CREATE TABLE aims_ast_results (
    ast_result_id VARCHAR(64) PRIMARY KEY,
    isolate_id VARCHAR(64) REFERENCES aims_isolates_normalized(isolate_id),
    antimicrobial_code VARCHAR(32) NOT NULL,
    antimicrobial_name VARCHAR(64) NOT NULL,
    mic_numeric_ug_ml DECIMAL(8,4),
    sir_interpretation CHAR(1) CHECK (sir_interpretation IN ('S', 'I', 'R')),
    clsi_m100_edition VARCHAR(16) NOT NULL,
    molecular_marker_detected VARCHAR(64)
);

CREATE TABLE aims_hitl_dispositions (
    alert_id VARCHAR(64) PRIMARY KEY,
    rule_code VARCHAR(8) NOT NULL,
    isolate_id VARCHAR(64) REFERENCES aims_isolates_normalized(isolate_id),
    reviewer_credential VARCHAR(64) NOT NULL, -- e.g., M(ASCP), PharmD
    disposition_status VARCHAR(32) NOT NULL,  -- CONFIRMED_ESCALATE, WATCHLIST, OVERRIDE_ARTIFACT
    clinical_rationale TEXT NOT NULL,
    reviewed_timestamp TIMESTAMP NOT NULL
);
U.S. Clinical Laboratory & Diagnostic Platform Compatibility Specification
Engineered for non-disruptive, read-only ingestion from standard U.S. clinical microbiology instruments and Laboratory Information Systems (LIS).
Diagnostic Platform / Instrument Class Representative U.S. Systems Data Elements Mapped into AIMS Layer 1 Integration Pathway
Automated ID / AST Platforms BD Phoenix™ Automated Microbiology System
bioMérieux VITEK® 2 • Beckman Coulter MicroScan		 Organism ID, numeric MIC dilutions, S/I/R breakpoint calls, expert-rule phenotype flags (ESBL, CRE, MRSA) HL7 v2.5.1 ORU^R01 / Flat-File CSV LIS Export → AIMS Layer 1 Normalization Schema
High-Throughput Molecular Diagnostics Hologic Panther® / Panther Fusion® System
Cepheid GeneXpert® • BioFire® FilmArray®		 Target nucleic-acid amplification results, resistance gene markers (blaKPC, blaNDM, blaOXA-48, mecA, vanA/B) Genotype–Phenotype Concordance Mapping (AIMS Layer 2 & Rule R4 Discordance Check)
Hospital LIS & Stewardship Systems Epic Beaker® • Oracle Health (Cerner) PathNet • Sunquest / Clinisys Specimen source, collection timestamp, inpatient unit/ward location, deduplication encounter keys Read-Only Parallel Sandbox Evaluation (Zero Disruption to Primary Clinical Reporting)
U.S. Cloud Sandbox & Technical Infrastructure Collaboration — MannaSync Solutions Inc.
Supporting U.S. clinical-laboratory readiness, interactive benchmark verification, and multi-institution dissemination.

To support the transition of the validated AIMS Framework from its external observational validation (842 clinical isolates, Exhibit 34) into U.S. clinical microbiology and antimicrobial-stewardship environments, MannaSync Solutions Inc. (Dayton, Ohio, U.S.A.) provides U.S. cloud sandbox hosting, interactive verification infrastructure for the AIMS-EVAL-2025-01 dataset, and HL7/CSV ingestion pipeline testing.

Intellectual Property & Governance Notice: All intellectual property, SQL schemas, R1–R5 rule specifications, and scientific authorship of the AIMS Framework remain the sole and exclusive property of Adaora Nkiruka Ofole, M.S., M.B.A., M(ASCP). No patient protected health information (PHI) is stored or transmitted within this public demonstration portal.

Peer-Reviewed Scholarship, Conference Acceptances & Institutional Validation Record
Verifiable record of scientific development, external validation, and professional dissemination.
Milestone / Venue Identifier / Citation Status & Role Significance to U.S. AMR Surveillance
ABRCMS 2026
(Organized by American Society for Microbiology)		 Submission No. 26-TAA-1389
(Co-authored with Dr. Joseph Panzarella, Yeshiva University)		 Accepted for Presentation National scientific dissemination of the AIMS Framework to U.S. microbiology researchers and diagnostic stakeholders.
FIS International 2026
(Federation of Infection Societies, Glasgow, UK)		 Acceptance No. 347
(Registered & Confirmed)		 Accepted Poster Presentation International peer review by infectious-disease clinicians, clinical microbiologists, and AMR surveillance specialists.
ASM / IDSA IMARI 2027
(Interdisciplinary Meeting on AMR & Innovation)		 Proposal No. 87470
(Registered Participant)		 Registered for U.S. Collaborative Engagement Direct engagement with U.S. infectious-disease specialists and diagnostic technology innovators.
Prospective Observational Clinical Validation
(Southern Delta University, Nigeria)		 Executed Protocol, QI Charter & MOA
(842 De-Identified Clinical Isolates)		 Completed (96.8% Concordance, κ = 0.91) Demonstrated real-world transferability, 95.4% sensitivity, 97.9% specificity, 14 early-warning signals, and -38 min delay reduction.
First-Author Peer-Reviewed Critical Review
(Arch. Curr. Res. Int., 2026)		 Ofole, A.N. & Ayanru, D. (2026). 26(9):418–439 Published (First Author) Examines AI applications, governance, and implementation barriers across pre-analytical, analytical, and post-analytical microbiology workflows.